YD Bio Ltd (YDES): Financial results for H1 2026

YD Bio Ltd (YDES) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026 TAIPEI, Taiwan, Aug. 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detec

Event · Earnings
Original reporting
Published Aug 31, 2026, 9:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 10:08 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$YDES
Neutral
medium confidence
Mentioned
$YDES
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 6-K
Decision brief

The 30-second read

$YDESNeutralMed
01

Why it matters

The H1 2026 results show rapid top‑line expansion but reliance on non‑cash accounting items, suggesting a nuanced market reaction.

02

Market read

First‑hand earnings data for a micro‑cap biotech; may influence short‑term trading and sector sentiment.

03

What to watch

Supply‑chain concentration risk and rising cost of revenue could pressure margins despite revenue growth.

Relevance 7/10Novelty 7/10Timing: post‑earnings release Aug 31 2026

Background

YD Bio Ltd (Nasdaq: YDES) is a Taiwan‑based biotech focusing on DNA‑methylation cancer detection and ophthalmic products.

Company-level read

Ticker impact

$YDESNeutralMedium confidence
Context

YD Bio Ltd released its unaudited H1 2026 earnings via a SEC Form 6‑K, reporting a 315% revenue jump to $847k and a swing to $6.7 million net income driven by fair‑value gains on warrant liabilities.

Expected impact

Potential modest upside if investors focus on top‑line growth; downside risk if they discount the non‑cash warrant gain.

Evidence & confidence

Revenue growth is strong, yet earnings are inflated by accounting adjustments, leading to mixed market reaction.

Market effects

Highlights accelerating growth in the DNA‑methylation diagnostics niche, potentially benefiting peer biotech firms.

Positive for Taiwan‑listed biotech exposure, may lift regional biotech indices.

Limited; primarily relevant to investors tracking niche cancer‑diagnostic companies.

Counterpoint

The net income is driven by a one‑time warrant fair‑value gain, so the earnings quality remains weak.

Key entities

  • Dr. Ethan Shen

    Chairman and CEO of YD Bio, provided commentary on the earnings release.

Related articles

$LUCYMedAI 8/10

Top Biotech Gainers: LUCY Shines, SEER Gets Takeover Offer, OFIX, ENOV Rally On CMS Update

Biotech gainers: Innovative Eyewear (LUCY) rose 63% after preliminary Q2 2026 net sales of ~$0.99M (+71% YoY) and new retail orders; Seer (SEER) jumped 35% on an unsolicited $2.45/share cash takeover proposal plus contingent value rights; Orthofix (OFIX) and Enovis (ENOV) gained 16%/15% after CMS withdrew reimbursement changes for non-invasive bone growth stimulators.

$PANWHighAI 9/10

Palo Alto Networks Reports Fiscal First Quarter 2027 Financial Results

Palo Alto Networks Inc (PANW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Palo Alto Networks Reports Fiscal First Quarter 2027 Financial Results SANTA CLARA, Calif., Nov. 18, 2026 — Palo Alto Networks ® (NASDAQ: PANW), the global AI cybersecurity leader, announced today financial results for its fiscal first quarter ended October 31, 2026.

$IPARMedAI 8/10

INTERPARFUMS, INC. ANNOUNCES FULL YEAR 2027 GUIDANCE

INTERPARFUMS INC (IPAR) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 FOR IMMEDIATE RELEASE INTERPARFUMS, INC. ANNOUNCES FULL YEAR 2027 GUIDANCE New York, New York, November 18, 2026, Interparfums, Inc. (NASDAQ GS: IPAR) (“Interparfums” or the “Company”) today announced initial guidance for its fiscal year ending December 31, 2027. In

$WWDMedAI 8/10

Woodward falls on soft guidance despite fourth quarter beat

Woodward Inc (WWD) reported Q4 2026 adjusted EPS of $2.83, beating estimates by $0.30, and revenue of $1.2B, up 17% YoY. However, its fiscal 2027 guidance fell short of expectations, with EPS projected at $10.20-$10.70, below the $10.76 consensus. Shares dropped 1.7% in after-hours trading. The company reported full-year 2026 adjusted EPS of $9.78, up 42% YoY, and net sales of $4.4B, up 22% YoY.

$KRNTMedAI 8/10

Kornit (KRNT) Q3 2026 Earnings Call Transcript

Kornit (KRNT) reported Q3 2026 revenue of $58.3M, up 9.8% YoY. The company highlighted growth in recurring revenue, with 80% of revenue being recurring or highly recurring. Annual recurring revenue (ARR) reached $39.4M, up 83% YoY. Kornit expects Q4 revenue between $60M and $65M, with adjusted EBITDA margin between 6.5% and 9%. The company is seeing strong adoption of its all-inclusive click (AIC) model and is expanding its customer base, including traditional screen printers.

$SNEXMedAI 8/10

StoneX Group falls after fourth quarter earnings miss

StoneX Group Inc. (SNEX) reported Q4 earnings of $0.66 per share, missing estimates of $0.81. Revenue rose 12% YoY to $655.2M, but net income fell 2% to $84.2M. Full-year 2026 results showed record net income of $525.4M, up 72% YoY, and revenue of $2.9B, up 43% YoY. The stock dropped 6.2% in after-hours trading.